

Amendment Approval Form

Date: March 12, 2026

Amendment ID: [Pro00112293_AME14](#)

Principal Investigator: [Oleksa Rewa](#)

Study ID: Pro00112293

Shaun Cowan / pSite00000044 (University of Alberta)

Site Principal Investigator / Study ID: Janek Senaratne / pSite00000157 (University of Alberta)

Victor Dong / pSite-22-0043 (University of Calgary)

Study Title: Midodrine for the early liberation from vasopressor support in the ICU – LIBERATE

Protocol Number: version 6.0

Sponsor/Funding Agency: University Hospital Foundation
University of Alberta Faculty of Medicine and Dentistry

Approval Expiry Date: October 5, 2026

Thank you for submitting an amendment request to the Health Research Ethics Board - Biomedical Panel. The following has been reviewed and approved on behalf of the committee:

Approved Documents (Lead site):

Consent Forms

[LIBERATE Multisite Information Sheet and Consent Form_V4.0_November_20_2025_CLEAN.docx](#)

Approved Documents (All sites):

Protocol/Research Proposal

[LIBERATE multi-site Protocol v6.0_20 Nov2025 - CLEAN.docx](#)

[CTA-N Cover Letter_protocol 5.0 not used_signed \(1\).pdf](#)

Health Canada No Objection Letter

[303252_apr.pdf](#)

Other Documents

[Effective_Canada \(English\) EQ-5D-5L Paper Interviewer Administration v1.1.docx](#)

Note: Approval for an **amendment** does not change the original approval date of a study.

The membership of the Health Research Ethics Board - Biomedical Panel complies with the membership requirements for research ethics boards as defined in Division 5 of the Food and Drug Regulations and the Tri Council Policy Statement. The HREB - Biomedical Panel carries out its functions in a manner consistent with Good Clinical Practices.

Approval by the REB does not constitute authorization to initiate the conduct of this research. The Principal Investigator is responsible for ensuring required approvals from other involved organizations (e.g., Alberta Health Services, Covenant Health, community organizations, school boards) are obtained, before the research begins.

Sincerely,

Donald W. Morrish, MD, PhD, FRCPC
Associate Chair, HREB Biomedical

Note: This correspondence includes an electronic signature (validation and approval via an online system).